GlassScriptPhysician profile
Gregory N Mrozinski
NPI 1124177621
$1,369.25
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.64 · 2021: $564 · 2022: $363 · 2023: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $441.92 | 2021-2023 | Farxiga, Breztri |
| Abbvie INC. | $304.05 | 2021-2023 | |
| Lilly USA, LLC | $174.15 | 2021-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.42 | 2021-2023 | Xifaxan |
| Novo Nordisk INC | $63.81 | 2022-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.12 | 2019-2021 | |
| Antares Pharma, INC. | $36.78 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.26 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.86 | 2022 | |
| Abbott Laboratories | $21.19 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.04 | 2023 | Spravato |
| Glaxosmithkline, LLC. | $17.48 | 2021 | |
| Redhill Biopharma INC. | $14.98 | 2021 | |
| Amgen INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mrozinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.